CuraSen Therapeutics has commenced its Phase IIa proof-of-concept trial of CuraAX (CST-3056) with dosing of the first patient ...
TipRanks on MSN
Regeneron’s New Phase 3 Study on Mibavademab: A Potential Game-Changer for Generalized Lipodystrophy
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a critical study ...
Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...
From creating flexible gadgets to better medicines, the art of bending crystals is reshaping technology and health, and at ...
The study assessed OV329 in 68 healthy subjects, comprising 51 individuals receiving active treatment and 17 receiving placebo.
You may feel sleepy after drinking coffee if you have not gotten enough quality sleep. Coffee temporarily makes you feel ...
MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tvardi Therapeutics, Inc. (NASDAQ: TVRD) resulting from ...
Oral and inhaled biologics are gaining R&D investment due to patient acceptance and potential for home administration, with ...
Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...
SCYNEXIS Inc. (NASDAQ: SCYX) is one of the best long term penny stocks with huge upside potential. On September 30, SCYNEXIS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback